{"id":70542,"date":"2023-02-23T13:28:00","date_gmt":"2023-02-23T18:28:00","guid":{"rendered":"https:\/\/hitconsultant.net\/?p=70542"},"modified":"2023-02-24T13:36:54","modified_gmt":"2023-02-24T18:36:54","slug":"tempus-forms-multi-omics-collaboration-with-actuate-therapeutics","status":"publish","type":"post","link":"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/","title":{"rendered":"Tempus Forms Multi-omics Collaboration With Actuate Therapeutics"},"content":{"rendered":"\n
\"Cedars-Sinai<\/figure>\n\n\n\n

What You Should Know:<\/strong><\/p>\n\n\n\n

– Tempus<\/a>, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics<\/a>, in which datasets of different omic groups \u2013 genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone.<\/p>\n\n\n\n

– This multi-omics approach is being used by Actuate Therapeutics<\/a> in support of their Phase 1\/2 oncology study of elraglusib, a GSK-3\u03b2 inhibitor, which includes a randomized study in patients with metastatic pancreatic cancer.<\/p>\n\n\n\n

– The drug has shown clinical benefit for multiple advanced cancers. Tempus\u2019 diagnostic technology and multimodal (i.e., DNA, RNA, and imaging) data will support the discovery and validation of novel targets and biomarker profiles that will help determine which patients may respond better to the drug \u2013 demonstrating a new way in which precision medicine can be incorporated in clinical development.<\/p>\n","protected":false},"excerpt":{"rendered":"

What You Should Know: – Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups \u2013 genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a … Read More<\/a><\/p>\n","protected":false},"author":81,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"categories":[1117],"tags":[2433,3355,16940,12045,2581,2555,3605],"yoast_head":"\nTempus Forms Multi-omics Collaboration With Actuate Therapeutics<\/title>\n<meta name=\"description\" content=\"Tempus, the $10B AI and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tempus Forms Multi-omics Collaboration With Actuate Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Tempus, the $10B AI and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-23T18:28:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-24T18:36:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2021\/09\/Tempus-1500x788.png\" \/>\n<meta name=\"author\" content=\"Fred Pennic\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hitconsultant\" \/>\n<meta name=\"twitter:site\" content=\"@hitconsultant\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fred Pennic\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/\"},\"author\":{\"name\":\"Fred Pennic\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/person\/f7eaad30c9c560826bcbdd28d779118c\"},\"headline\":\"Tempus Forms Multi-omics Collaboration With Actuate Therapeutics\",\"datePublished\":\"2023-02-23T18:28:00+00:00\",\"dateModified\":\"2023-02-24T18:36:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/\"},\"wordCount\":158,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/hitconsultant.net\/#organization\"},\"keywords\":[\"Artificial Intelligence\",\"cancer\",\"dna\",\"genomics\",\"Oncology\",\"Precision Medicine\",\"Tempus\"],\"articleSection\":[\"Health IT\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/\",\"url\":\"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/\",\"name\":\"Tempus Forms Multi-omics Collaboration With Actuate Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/hitconsultant.net\/#website\"},\"datePublished\":\"2023-02-23T18:28:00+00:00\",\"dateModified\":\"2023-02-24T18:36:54+00:00\",\"description\":\"Tempus, the $10B AI and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics\",\"breadcrumb\":{\"@id\":\"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hitconsultant.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Health IT\",\"item\":\"https:\/\/hitconsultant.net\/category\/health-it\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Tempus Forms Multi-omics Collaboration With Actuate Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hitconsultant.net\/#website\",\"url\":\"https:\/\/hitconsultant.net\/\",\"name\":\"\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/hitconsultant.net\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hitconsultant.net\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/hitconsultant.net\/#organization\",\"name\":\"HIT Consultant Media\",\"url\":\"https:\/\/hitconsultant.net\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png\",\"contentUrl\":\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png\",\"width\":\"1024\",\"height\":\"772\",\"caption\":\"HIT Consultant Media\"},\"image\":{\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409\",\"https:\/\/twitter.com\/hitconsultant\",\"http:\/\/www.linkedin.com\/company\/2489253\",\"https:\/\/www.pinterest.com\/hitconsultant\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/person\/f7eaad30c9c560826bcbdd28d779118c\",\"name\":\"Fred Pennic\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e1e715257b8b39a7b4aa16e8e0d458ea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e1e715257b8b39a7b4aa16e8e0d458ea?s=96&d=mm&r=g\",\"caption\":\"Fred Pennic\"},\"description\":\"Fred Pennic is the Founder and Editor-in-Chief of HIT Consultant. Fred is a seasoned health IT strategist with fourteen years of experience in providing advisory services to executive leadership at hospitals and health systems. Some of his previous clients include Mayo Clinic, Stanford Hospital and Health Clinics, Northwell Health, Trinity Health.\",\"sameAs\":[\"https:\/\/hitconsultant.net\"],\"url\":\"https:\/\/hitconsultant.net\/author\/fpennic\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tempus Forms Multi-omics Collaboration With Actuate Therapeutics","description":"Tempus, the $10B AI and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Tempus Forms Multi-omics Collaboration With Actuate Therapeutics","og_description":"Tempus, the $10B AI and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics","og_url":"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/","article_publisher":"https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409","article_published_time":"2023-02-23T18:28:00+00:00","article_modified_time":"2023-02-24T18:36:54+00:00","og_image":[{"url":"https:\/\/hitconsultant.net\/wp-content\/uploads\/2021\/09\/Tempus-1500x788.png"}],"author":"Fred Pennic","twitter_card":"summary_large_image","twitter_creator":"@hitconsultant","twitter_site":"@hitconsultant","twitter_misc":{"Written by":"Fred Pennic","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/#article","isPartOf":{"@id":"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/"},"author":{"name":"Fred Pennic","@id":"https:\/\/hitconsultant.net\/#\/schema\/person\/f7eaad30c9c560826bcbdd28d779118c"},"headline":"Tempus Forms Multi-omics Collaboration With Actuate Therapeutics","datePublished":"2023-02-23T18:28:00+00:00","dateModified":"2023-02-24T18:36:54+00:00","mainEntityOfPage":{"@id":"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/"},"wordCount":158,"commentCount":0,"publisher":{"@id":"https:\/\/hitconsultant.net\/#organization"},"keywords":["Artificial Intelligence","cancer","dna","genomics","Oncology","Precision Medicine","Tempus"],"articleSection":["Health IT"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/","url":"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/","name":"Tempus Forms Multi-omics Collaboration With Actuate Therapeutics","isPartOf":{"@id":"https:\/\/hitconsultant.net\/#website"},"datePublished":"2023-02-23T18:28:00+00:00","dateModified":"2023-02-24T18:36:54+00:00","description":"Tempus, the $10B AI and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics","breadcrumb":{"@id":"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/hitconsultant.net\/2023\/02\/23\/tempus-forms-multi-omics-collaboration-with-actuate-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hitconsultant.net\/"},{"@type":"ListItem","position":2,"name":"Health IT","item":"https:\/\/hitconsultant.net\/category\/health-it\/"},{"@type":"ListItem","position":3,"name":"Tempus Forms Multi-omics Collaboration With Actuate Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/hitconsultant.net\/#website","url":"https:\/\/hitconsultant.net\/","name":"","description":"","publisher":{"@id":"https:\/\/hitconsultant.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hitconsultant.net\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/hitconsultant.net\/#organization","name":"HIT Consultant Media","url":"https:\/\/hitconsultant.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/","url":"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png","contentUrl":"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png","width":"1024","height":"772","caption":"HIT Consultant Media"},"image":{"@id":"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409","https:\/\/twitter.com\/hitconsultant","http:\/\/www.linkedin.com\/company\/2489253","https:\/\/www.pinterest.com\/hitconsultant\/"]},{"@type":"Person","@id":"https:\/\/hitconsultant.net\/#\/schema\/person\/f7eaad30c9c560826bcbdd28d779118c","name":"Fred Pennic","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hitconsultant.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e1e715257b8b39a7b4aa16e8e0d458ea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e1e715257b8b39a7b4aa16e8e0d458ea?s=96&d=mm&r=g","caption":"Fred Pennic"},"description":"Fred Pennic is the Founder and Editor-in-Chief of HIT Consultant. Fred is a seasoned health IT strategist with fourteen years of experience in providing advisory services to executive leadership at hospitals and health systems. Some of his previous clients include Mayo Clinic, Stanford Hospital and Health Clinics, Northwell Health, Trinity Health.","sameAs":["https:\/\/hitconsultant.net"],"url":"https:\/\/hitconsultant.net\/author\/fpennic\/"}]}},"_links":{"self":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/posts\/70542"}],"collection":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/users\/81"}],"replies":[{"embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/comments?post=70542"}],"version-history":[{"count":0,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/posts\/70542\/revisions"}],"wp:attachment":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/media?parent=70542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/categories?post=70542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/tags?post=70542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}